Theriva Biologics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Theriva Biologics, Inc. (TOVX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-11
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$3.22M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$2.04M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$3.51M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$4.36M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$25.25M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$25.65M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$18.35M.
- Theriva Biologics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$20.02M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.22M 10-Q · filed 2026-08-11 | -$5.26M 10-Q · filed 2026-08-11 | -$8.77M derived: sum of 3 quarters · filed 2026-08-11 | -$13.13M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$2.04M 10-Q · filed 2026-05-05 | -$5.55M derived: sum of 2 quarters · filed 2026-05-05 | -$9.91M derived: sum of 3 quarters · filed 2026-05-05 | -$22.97M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$7.87M derived: sum of 2 quarters · filed 2026-03-12 | -$20.93M derived: sum of 3 quarters · filed 2026-08-11 | -$25.25M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$4.36M 10-Q · filed 2025-11-12 | -$17.42M derived: sum of 2 quarters · filed 2026-08-11 | -$21.74M 10-Q · filed 2025-11-12 | -$26.19M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$13.06M 10-Q · filed 2026-08-11 | -$17.38M 10-Q · filed 2026-08-11 | -$21.83M derived: sum of 3 quarters · filed 2026-08-11 | -$29.55M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$4.32M 10-Q · filed 2026-05-05 | -$8.77M derived: sum of 2 quarters · filed 2026-05-05 | -$16.50M derived: sum of 3 quarters · filed 2026-05-05 | -$24.81M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | -$4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$12.17M derived: sum of 2 quarters · filed 2026-03-12 | -$20.49M derived: sum of 3 quarters · filed 2026-03-12 | -$25.65M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | -$7.73M 10-Q · filed 2025-11-12 | -$16.04M derived: sum of 2 quarters · filed 2025-11-12 | -$21.21M 10-Q · filed 2025-11-12 | -$26.69M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$8.32M 10-Q · filed 2025-08-11 | -$13.48M 10-Q · filed 2025-08-11 | -$18.97M derived: sum of 3 quarters · filed 2025-08-11 | -$22.27M derived: sum of 4 quarters · filed 2025-08-11 | |||
| 2024-03-31 | -$5.17M 10-Q · filed 2025-05-14 | -$10.65M derived: sum of 2 quarters · filed 2025-05-14 | -$13.95M derived: sum of 3 quarters · filed 2025-05-14 | -$19.04M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$8.79M derived: sum of 2 quarters · filed 2025-03-06 | -$13.87M derived: sum of 3 quarters · filed 2025-03-06 | -$18.35M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | -$3.30M 10-Q · filed 2024-11-12 | -$8.39M derived: sum of 2 quarters · filed 2024-11-12 | -$12.86M 10-Q · filed 2024-11-12 | -$19.31M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$5.08M 10-Q · filed 2024-08-13 | -$9.56M 10-Q · filed 2024-08-13 | -$16.01M derived: sum of 3 quarters · filed 2024-08-13 | -$20.84M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$4.48M 10-Q · filed 2024-05-07 | -$10.92M derived: sum of 2 quarters · filed 2024-05-07 | -$15.75M derived: sum of 3 quarters · filed 2024-05-07 | -$20.23M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | -$6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$11.28M derived: sum of 2 quarters · filed 2024-03-25 | -$15.75M derived: sum of 3 quarters · filed 2024-03-25 | -$20.02M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | -$4.83M 10-Q · filed 2023-11-13 | -$5.19M 10-Q · filed 2022-11-10 | -$9.31M derived: sum of 2 quarters · filed 2023-11-13 | -$13.58M 10-Q · filed 2023-11-13 | -$14.43M 10-Q · filed 2022-11-10 | -$18.84M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$4.48M 10-Q · filed 2023-08-08 | -$4.97M 10-Q · filed 2022-08-11 | -$8.75M 10-Q · filed 2023-08-08 | -$9.24M 10-Q · filed 2022-08-11 | -$14.01M derived: sum of 3 quarters · filed 2023-08-08 | -$17.29M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$4.27M 10-Q · filed 2023-05-11 | -$9.54M derived: sum of 2 quarters · filed 2023-05-11 | -$12.81M derived: sum of 3 quarters · filed 2023-05-11 | -$16.00M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$8.54M derived: sum of 2 quarters · filed 2023-03-30 | -$11.73M derived: sum of 3 quarters · filed 2023-03-30 | -$23.19M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$3.27M 10-Q · filed 2022-11-10 | -$6.47M derived: sum of 2 quarters · filed 2022-11-10 | -$17.93M 10-Q · filed 2022-11-10 | -$21.05M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$3.19M 10-Q · filed 2022-08-11 | -$14.65M 10-Q · filed 2022-08-11 | -$17.77M derived: sum of 3 quarters · filed 2022-08-11 | -$20.46M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | -$11.46M 10-Q · filed 2022-05-16 | -$14.58M derived: sum of 2 quarters · filed 2022-05-16 | -$17.26M derived: sum of 3 quarters · filed 2022-05-16 | -$20.59M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$5.80M derived: sum of 2 quarters · filed 2022-03-16 | -$9.13M derived: sum of 3 quarters · filed 2022-03-16 | -$12.56M 10-K · filed 2022-03-16 | |||
| 2020-09-30 | -$2.69M 10-Q · filed 2021-11-03 | -$6.01M derived: sum of 2 quarters · filed 2021-11-03 | -$9.44M 10-Q · filed 2021-11-03 | -$12.58M derived: sum of 4 quarters · filed 2021-11-03 | |||
| 2020-06-30 | -$3.32M 10-Q · filed 2021-08-05 | -$6.75M 10-Q · filed 2021-08-05 | -$9.89M derived: sum of 3 quarters · filed 2021-08-05 | -$15.15M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | -$3.43M 10-Q · filed 2021-05-05 | -$6.57M derived: sum of 2 quarters · filed 2021-05-05 | -$11.82M derived: sum of 3 quarters · filed 2021-05-05 | -$15.53M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | -$3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$8.39M derived: sum of 2 quarters · filed 2021-03-04 | -$12.10M derived: sum of 3 quarters · filed 2021-03-04 | -$16.08M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | -$5.25M 10-Q · filed 2020-11-10 | -$8.96M derived: sum of 2 quarters · filed 2020-11-10 | -$12.93M 10-Q · filed 2020-11-10 | -$27.85M derived: sum of 4 quarters · filed 2020-11-10 | |||
| 2019-06-30 | -$3.71M 10-Q · filed 2020-08-06 | -$7.68M 10-Q · filed 2020-08-06 | -$22.60M derived: sum of 3 quarters · filed 2020-08-06 | -$26.34M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | -$3.97M 10-Q · filed 2020-05-05 | -$18.89M derived: sum of 2 quarters · filed 2020-05-05 | -$22.63M derived: sum of 3 quarters · filed 2020-05-05 | -$26.89M derived: sum of 4 quarters · filed 2020-05-05 | |||
| 2018-12-31 | -$14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | -$18.66M derived: sum of 2 quarters · filed 2020-02-20 | -$22.91M derived: sum of 3 quarters · filed 2020-02-20 | -$25.29M 10-K · filed 2020-02-20 | |||
| 2018-09-30 | -$3.74M 10-Q · filed 2019-11-04 | -$8.00M derived: sum of 2 quarters · filed 2019-11-04 | -$10.38M 10-Q · filed 2019-11-04 | -$7.58M derived: sum of 4 quarters · filed 2019-11-04 | |||
| 2018-06-30 | -$4.26M 10-Q · filed 2019-08-08 | -$6.63M 10-Q · filed 2019-08-08 | -$3.84M derived: sum of 3 quarters · filed 2019-08-08 | -$21.67M derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-03-31 | -$2.38M 10-Q · filed 2019-05-08 | $414.00K derived: sum of 2 quarters · filed 2019-05-08 | -$17.41M derived: sum of 3 quarters · filed 2019-05-08 | -$21.66M derived: sum of 4 quarters · filed 2019-05-08 | |||
| 2017-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$15.03M derived: sum of 2 quarters · filed 2019-02-27 | -$19.29M derived: sum of 3 quarters · filed 2019-02-27 | -$22.14M 10-K · filed 2019-02-27 | |||
| 2017-09-30 | -$17.82M 10-Q · filed 2018-11-08 | -$22.08M derived: sum of 2 quarters · filed 2018-11-08 | -$24.93M 10-Q · filed 2018-11-08 | -$27.30M derived: sum of 4 quarters · filed 2018-11-08 | |||
| 2017-06-30 | -$4.25M 10-Q · filed 2018-08-08 | -$7.10M 10-Q · filed 2018-08-08 | -$9.48M derived: sum of 3 quarters · filed 2018-08-08 | -$17.83M derived: sum of 4 quarters · filed 2018-08-08 | |||
| 2017-03-31 | -$2.85M 10-Q · filed 2018-05-08 | -$5.22M derived: sum of 2 quarters · filed 2018-05-08 | -$13.57M derived: sum of 3 quarters · filed 2018-05-08 | -$19.34M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2016-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$10.73M derived: sum of 2 quarters · filed 2018-02-22 | -$16.49M derived: sum of 3 quarters · filed 2018-02-22 | -$27.25M 10-K · filed 2018-02-22 | |||
| 2016-09-30 | -$8.35M 10-Q · filed 2017-11-01 | -$14.12M derived: sum of 2 quarters · filed 2017-11-01 | -$24.88M 10-Q · filed 2017-11-01 | -$35.94M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-06-30 | -$5.76M 10-Q · filed 2017-08-03 | -$16.84M 10-Q · filed 2017-08-03 | -$27.59M derived: sum of 3 quarters · filed 2018-02-22 | -$34.37M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-03-31 | -$10.85M 10-Q · filed 2017-05-04 | -$21.83M derived: sum of 2 quarters · filed 2018-02-22 | -$28.60M derived: sum of 3 quarters · filed 2018-02-22 | -$42.22M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2015-12-31 | -$10.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$17.76M derived: sum of 2 quarters · filed 2018-02-22 | -$31.38M derived: sum of 3 quarters · filed 2018-02-22 | -$43.74M 10-K · filed 2018-02-22 | |||
| 2015-09-30 | -$6.77M 10-Q · filed 2016-11-01 | -$20.40M derived: sum of 2 quarters · filed 2016-11-01 | -$32.76M 10-Q · filed 2016-11-01 | ||||
| 2015-06-30 | -$13.62M 10-Q · filed 2016-08-03 | -$25.98M 10-Q · filed 2016-08-03 | |||||
| 2014-09-30 | -$4.91M 10-Q · filed 2015-11-05 | -$13.30M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |